Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;46(1):210-213.
doi: 10.1007/s11096-023-01656-z. Epub 2023 Oct 26.

How to manage the dose of drugs in cancer patients with acute kidney injury, practical recommendations

Nicolas Janus  1 , Pierre-Yves Desplanques  2
Affiliations

How to manage the dose of drugs in cancer patients with acute kidney injury, practical recommendations

Nicolas Janus et al. Int J Clin Pharm. 2024 Feb.

Abstract

Acute kidney injury (AKI) and chronic kidney disease (CKD) are common in cancer patients. AKI is a brutal and reversible condition which makes it hard to manage from a pharmacological perspective when patients are receiving anticancer regimens and other supportive care drugs, such as anticoagulants, analgesics and other drugs. In contrast to CKD, which is a slow progressive disease, there is no clear guidance on how to manage and/or modify the dosage of drugs during AKI. Indeed, the slow progression of CKD allows physicians to monitor the renal function by using the glomerular filtration rate. Consequently, publications have explored the management of drugs in cancer patients with CKD, which is currently not the same for AKI. There are no recommendations or suggestions on how to manage drug doses in case of AKI in cancer patients. This commentary explores the different options to manage drugs (anticancer drugs, anticoagulants, and other supportive care drugs) during AKI in cancer patients.

Keywords: Acute kidney injury; Antineoplastic agents; Nephrology; Oncology.

PubMed Disclaimer

References

    1. Janus N, Launay-Vacher V, Byloos E, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815–21. https://doi.org/10.1038/sj.bjc.6605979 . - DOI - PubMed - PMC
    1. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376–84. https://doi.org/10.1002/cncr.22904 . - DOI - PubMed
    1. Travassos PNC, de Barros Silva PG, Freitas MO, et al. Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment. Support Care Cancer. 2022;30(9):7271–80. https://doi.org/10.1007/s00520-022-07159-3 . - DOI - PubMed
    1. Mahmoodi BK, Gansevoort RT, Naess IA, et al. Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation. 2012;126(16):1964–71. https://doi.org/10.1161/CIRCULATIONAHA.112.113944 . - DOI - PubMed - PMC
    1. Ishigami J, Grams ME, Naik RP, et al. Chronic kidney disease and risk for gastrointestinal bleeding in the community: the atherosclerosis risk in communities (ARIC) study. Clin J Am Soc Nephrol. 2016;11(10):1735–43. https://doi.org/10.2215/CJN.02170216 . - DOI - PubMed - PMC

LinkOut - more resources